Professor Greg Hannon is today announced as the new director of the Cancer Research UK Cambridge Institute.
Nanobots that patrol our bodies, killer immune cells hunting and destroying cancer cells, biological scissors that cut out defective genes: these are just some of technologies that Cambridge researchers are developing which are set to revolutionise medicine in the future.
Gene editing using ‘molecular scissors’ that snip out and replace faulty DNA could provide an almost unimaginable future for some patients: a complete cure. Cambridge researchers are working towards making the technology cheap and safe, as well as examining the ethical and legal issues surrounding one of the most exciting medical advances of recent times.
Scientists at the University of Cambridge have developed a new statistical model which estimates kidney function in patients with cancer. This is the most accurate model for estimating kidney function yet developed and should help cancer specialists treat their patients more safely and improve the accuracy of chemotherapy dosing. The model is now available free online.
Scientists have uncovered why Zika virus may specifically target neural stem cells in the developing brain, potentially leading to microcephaly – a potentially serious birth defect where the brain fails to develop properly, leading to a smaller head.
Cambridge scientists have received two of the biggest funding grants ever awarded by Cancer Research UK, with the charity set to invest £40 million over the next five years in two ground-breaking research projects in the city.
Cambridge scientists are set to receive a major cash injection from Cancer Research UK, which has announced plans to invest over £41 million over the next five years at the Cancer Research UK Cambridge Centre, one of the University of Cambridge’s Strategic Research Initiatives. The funding will help support ground-breaking work as part of the development of a unique chain of research hubs around the UK.
A weight loss condition that affects patients with cancer has provided clues as to why cancer immunotherapy – a new approach to treating cancer by boosting a patient’s immune system – may fail in a substantial number of patients.